Skip to content
lsd.com
CompletedN/A

Chart Review of Patients Undergoing Ketamine Treatments for Depression

NCT07099235 · Sunnybrook Health Sciences Centre

Closed to entry
Status
Not accepting participants
Not applicable
Phase
250
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression. This retrospective, observational study aims to conduct a chart review on patients receiving ketamine in a naturalistic setting to develop our understanding of ketamine as an interventional approach for treatment-resistant depression.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Patient Health Questionnaire-9 item

    Measured over Treatment Day 1 to Day 8, an average of 4 weeks.

  • Beck's Depression Inventory-II

    Measured over Treatment Day 1 to Day 8, an average of 4 weeks.

  • Generalized Anxiety Disorder-7 item

    Measured over Treatment Day 1 to Day 8, an average of 4 weeks.

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Age ≥ 18 * Able to provide informed consent * Patient diagnosed with treatment-resistant depression * Outpatient recommended and approved by psychiatrist for ketamine treatment * Individuals who have previously received ECT, rTMS or any other neuromodulation can also receive ketamine Exclusion Criteria: * History of psychosis/comorbid psychiatric disorders/psychotic depression/dissociative syndromes, significant personality disorder, as clinically assessed by psychiatrist * Using non-prescribed substance (e.g., cannabis) or alcohol use within the preceding 48 hours of treatment * History of substance misuse and/or dependence, including chronic alcohol abuse * Previous ketamine use * Acute dementia/delirium * Pregnancy/breastfeeding * Previous sensitivity to ketamine or related compounds * Unstable medical condition which may require anesthesia consult * History of elevated intracranial pressure or cerebrovascular accident * Recent (within 6 weeks) major cardiovascular event (such as myocardial infarction)

Where

1 study site

FacilityCityRegionCountry
Ontario Ketamine and Infusion Centre - Toronto SiteMississaugaOntarioCanada

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07099235 on ClinicalTrials.gov →

Last updated in the registry 2025-08-01. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

All 4 trials from Sunnybrook Health Sciences Centre →